Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Biomed. environ. sci ; Biomed. environ. sci;(12): 331-339, 2016.
Article in English | WPRIM | ID: wpr-258815

ABSTRACT

<p><b>OBJECTIVE</b>To explore the viral etiology of human breast cancer to determine whether there are novel molecular targets for gene therapy of breast cancer and provide evidence for the research of gene therapy and vaccine development for breast cancer.</p><p><b>METHODS</b>PCR was used to screen HPV16 and HPV18 oncogenes E6 and E7 in the SKBR3 cell line and in 76 paraffin embedded breast cancer tissue samples. RNA interference was used to knock down the expression of HPV18 E6 and E7 in SKBR3 cells, then the changes in the expression of cell-cycle related proteins, cell viability, colony formation, metastasis, and cell cycle progression were determined.</p><p><b>RESULTS</b>HPV18 oncogenes E6 and E7 were amplified and sequenced from the SKBR3 cells. Of the patient samples, 6.58% and 23.68% were tested to be positive for HPV18 E6 and HPV18 E7. In the cell culture models, the knockdown of HPV18 E6 and E7 inhibited the proliferation, metastasis, and cell cycle progression of SKBR3 cell. The knockdown also clearly affected the expression levels of cell cycle related proteins.</p><p><b>CONCLUSION</b>HPV was a contributor to virus caused human breast cancer, suggesting that the oncogenes in HPV were potential targets for gene therapy of breast cancer.</p>


Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Middle Aged , Base Sequence , Breast Neoplasms , Genetics , Therapeutics , Genetic Therapy , Methods , Oncogene Proteins, Viral , Genetics , Metabolism , Papillomaviridae , Physiology , Papillomavirus Infections , Genetics , Therapeutics , Sequence Alignment
2.
Zhonghua Bing Li Xue Za Zhi ; (12): 33-38, 2012.
Article in Chinese | WPRIM | ID: wpr-242002

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the expression and promoter methylation status of p73 gene in ovarian epithelial tumors and their clinicopathological correlations.</p><p><b>METHODS</b>Tissue microarrays (TMA) consisting of 68 ovarian cancers, 37 ovarian borderline tumors and 21 ovarian benign tumors were constructed. p73 expression was detected by immunohistochemistry (EnVision method). Fresh-frozen tissue samples from 13 cases of ovarian carcinomas and 5 cases of borderline tumors were evaluated for the presence of p73 promoter methylation using bisulfite sequencing.</p><p><b>RESULTS</b>Overall, 92.6% (63/68) ovarian carcinomas expressed p73, with a mean value of 32% (percentage of p73 positive cells in the tumor). The mean value of p73 expression rate (40%) in serous carcinoma (26/26) was higher than those of other cancer types (P = 0.006). The mean value of p73 expression rate (40%) in type II ovarian carcinoma was significantly higher than that in type I ovarian carcinoma (24%, P = 0.010). The expression of p73 was not associated with FIGO stage and histological grade (both P > 0.05). The mean values of p73 expression in ovarian borderline tumor (30/37) and benign tumor (12/21) were 16% and 15%, respectively. Of the two groups, the mean value of p73 expression rate in serous type was higher than that in mucous type (P = 0.003, P = 0.026). Ovarian carcinomas had a higher level of p73 expression than borderline tumors and benign tumors (both P < 0.05), while that between ovarian borderline tumors and benign tumors had no statistical difference (P > 0.05). Among serous tumors (49/53), the mean value of p73 expression in the carcinoma group (26/26) was significantly higher than those in the borderline tumor group (12/14) and benign tumor group (11/13; P = 0.024 and P = 0.002, respectively), while that between borderline tumor group and benign tumor group had no statistical difference (P = 0.428). Among mucous tumors (15/27), the mean value of p73 expression in carcinoma group (6/7) was higher than that in benign tumor group (1/8; P = 0.032). No statistical difference of p73 expression was seen between the carcinoma group and ovarian borderline tumor group (8/12) and between the borderline tumor group and benign tumor group (P = 0.234, P = 0.201, respectively). p73 promotor methylation was found in 8 of 13 cases of carcinomas but at different methylation levels with a mean value of 8.0%. Two of 5 ovarian borderline tumors showed detectable p73 promotor methylation with a mean value of 9.0%. Compared with the borderline tumors, ovarian carcinomas showed a similar p73 methylation level (P > 0.05). The p73 methylation level in ovarian carcinomas was not associated with histological type, pathogenetic type, histological grade and FIGO stage (all P > 0.05).</p><p><b>CONCLUSIONS</b>Most of ovarian epithelial tumors express p73 protein with mean values higher in ovarian carcinomas than those in the borderline and benign tumors. Ovarian serous carcinomas have the highest expression level of p73. A simple linear correlation does not exist between the promoter methylation and protein expression of p73.</p>


Subject(s)
Adult , Aged , Female , Humans , Middle Aged , Young Adult , Cystadenocarcinoma, Mucinous , Metabolism , Pathology , Cystadenocarcinoma, Serous , Metabolism , Pathology , Cystadenofibroma , Metabolism , Pathology , Cystadenoma, Mucinous , Metabolism , Pathology , Cystadenoma, Serous , Metabolism , Pathology , DNA Methylation , DNA-Binding Proteins , Metabolism , Gene Expression Regulation, Neoplastic , Immunohistochemistry , Neoplasm Grading , Neoplasm Staging , Neoplasms, Glandular and Epithelial , Metabolism , Pathology , Nuclear Proteins , Metabolism , Oligonucleotide Array Sequence Analysis , Ovarian Neoplasms , Metabolism , Pathology , Promoter Regions, Genetic , Tumor Protein p73 , Tumor Suppressor Proteins , Metabolism
3.
Zhonghua Bing Li Xue Za Zhi ; (12): 443-447, 2012.
Article in Chinese | WPRIM | ID: wpr-303551

ABSTRACT

<p><b>OBJECTIVE</b>To study the clinicopathologic features and differential diagnosis of perivascular epithelioid cell tumors (PEComas) occurring in the urinary system.</p><p><b>METHODS</b>The clinicopathologic features of 21 cases of PEComa from September 2002 to September 2010 occurring in the urinary system were retrospectively reviewed. Immunohistochemical study for HMB 45, S-100 protein, smooth muscle actin, desmin, Melan A and Ki-67 was carried out.</p><p><b>RESULTS</b>Amongst the 21 cases studied, there were 5 males and 16 females. The age of patients ranged from 16 to 76 years (median = 51.3 years). Twenty cases occurred in the kidney and 1 in the bladder. The predominant histopathologic subtype of renal PEComas was classic type (10/20), followed by epithelioid type (5/20), smooth muscle type (3/20), inflammatory type (1/20) and sclerosing type (1/20). Immunohistochemical study showed that HMB 45 and smooth muscle actin were positive in 95.2% (20/21) and 80.9% (17/21) cases, respectively. Melan A, desmin and S-100 protein were expressed in 71.4% (15/21), 61.9% (13/21) and 33.3% (7/21) cases, respectively. The mean proliferative index was 1.29% (range = 0 to 5%). HMB 45 and Melan A were expressed in all of the 5 cases of epithelioid PEComas, whereas smooth muscle actin and desmin were only expressed in one of them. There was no significant difference between epithelioid PEComas and non-epithelioid PEComas in the expression of HMB 45, Melan A, smooth muscle actin and desmin. Positive staining for HMB 45 and smooth muscle actin was demonstrated in the case of bladder PEComa.</p><p><b>CONCLUSIONS</b>PEComas of the urinary system predominantly affect the kidney. Epithelioid renal PEComas and bladder PEComa are relatively rare and have unique pathologic features. It is necessary to distinguish PEComas from other malignant tumors. Immunohistochemical study for HMB 45, Melan A and smooth muscle actin is helpful for confirmation of diagnosis.</p>


Subject(s)
Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Young Adult , Actins , Metabolism , Carcinoma, Renal Cell , Metabolism , Pathology , Desmin , Metabolism , Diagnosis, Differential , Gastrointestinal Stromal Tumors , Metabolism , Pathology , Immunohistochemistry , Kidney Neoplasms , Metabolism , Pathology , Leiomyosarcoma , Metabolism , Pathology , MART-1 Antigen , Metabolism , Melanoma , Metabolism , Pathology , Melanoma-Specific Antigens , Metabolism , Perivascular Epithelioid Cell Neoplasms , Metabolism , Pathology , S100 Proteins , Metabolism , Urinary Bladder Neoplasms , Metabolism , Pathology
4.
Zhonghua Bing Li Xue Za Zhi ; (12): 433-437, 2012.
Article in Chinese | WPRIM | ID: wpr-303553

ABSTRACT

<p><b>OBJECTIVES</b>To study the morphologic changes of fallopian tubal epithelium in patients with ovarian serous epithelial tumors and to explore the relationship between the tubal epithelial changes and tumorigenesis of serous ovarian carcinoma.</p><p><b>METHODS</b>The fallopian tubes in 79 cases of high-grade serous ovarian carcinoma, 12 cases of low-grade serous ovarian carcinoma, 16 cases of serous borderline ovarian tumor and 11 cases of non-ovarian benign tumors were serially examined under light microscope. Immunohistochemical study with EnVision method was used to detect the expression of p53 and bcl-2 protein in the fallopian tubal epithelium in all cases. The occurrences of secretory cell outgrowth (SCOUT), p53 signature, serous tubal intraepithelial carcinoma (STIC) and serous invasive carcinoma were analyzed.</p><p><b>RESULTS</b>SCOUT in tubal epithelium was observed in 60.8% (48/79) of the high-grade serous carcinoma group, 4/12 of the low-grade serous carcinoma group, 3/16 of the serous borderline tumor group and 2/11 of the non-ovarian benign tumor group (P = 0.001). P53 signature, STIC and serous invasive carcinoma occurred only in the fallopian tubal epithelium of patients with high-grade serous ovarian carcinoma, with the positive rates being 29.1% (23/79), 15.2% (12/79) and 44.3% (35/79), respectively. Of the 23 cases with p53 signature, 17 cases had solitary lesion and 6 cases involved more than two sites. A total of 33 p53 signature positive foci were found, with 22 foci located at fimbria and 11 at ampulla. Bcl-2 expression was demonstrated in 90.9% of those foci (30/33). Of the 12 patients with STIC, 7 cases were solitary and 5 cases involved more than two sites. A total of 18 STIC foci were found, with 16 foci located at fimbria and 2 at ampulla. All of them were positive for bcl-2.</p><p><b>CONCLUSIONS</b>SCOUT is found in fallopian tubal epithelium in patients with serous ovarian epithelial tumors, especially high-grade serious carcinoma. On the other hand, p53 signature, STIC and invasive serous carcinoma of tubal epithelium are observed only in patients with high-grade serous ovarian carcinoma, with a predilection of fimbrial involvement. Correlation exists between SCOUT, p53 signature, STIC and high-grade serous ovarian carcinomas. Bcl-2 and p53 immunostaining is helpful for demonstrating such lesions.</p>


Subject(s)
Adult , Aged , Female , Humans , Middle Aged , Cell Transformation, Neoplastic , Cystadenocarcinoma, Serous , Metabolism , Pathology , Epithelial Cells , Pathology , Epithelium , Pathology , Fallopian Tube Neoplasms , Metabolism , Pathology , Fallopian Tubes , Pathology , Immunohistochemistry , Neoplasm Staging , Ovarian Neoplasms , Metabolism , Pathology , Precancerous Conditions , Metabolism , Pathology , Proto-Oncogene Proteins c-bcl-2 , Metabolism , Tumor Suppressor Protein p53 , Metabolism
5.
Zhonghua Bing Li Xue Za Zhi ; (12): 694-697, 2011.
Article in Chinese | WPRIM | ID: wpr-358262

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the role of p57 and p53 immunohistochemistry in the differential diagnosis of hydropic abortion, partial hydatidiform mole and complete hydatidiform mole.</p><p><b>METHODS</b>Immunohistochemical stains (EnVision method) for p57 and p53 were performed in tissue samples of normal placenta chorionic villi (n=10), abortion chorionic villi (n=12), partial hydatidiform (n=23) and complete hydatidiform moles (n=20).</p><p><b>RESULTS</b>The expression of p57 was predominantly localized in the nuclei of villous cytotrophoblasts and stromal cells. The positive rates of p57 in normal placenta, hydropic abortion and partial hydatidiform mole were 10/10, 12/12, and 100% (23/23), respectively, with no significant difference among the groups (P>0.05). However, none of the complete hydatidiform moles analyzed exhibited p57 positivity in cytotrophoblasts and stromal cells. There was a significant difference between partial and complete hydatidiform moles (P<0.05). The expression of p53 was observed in the nuclei of cytotrophoblastic cells and intermediate trophoblasts. No p53 expression was seen in normal placenta and only 1 of 12 hydropic abortion showed p53 positivity. The positive rates of p53 expression in partial and complete hydatidiform mole were 60.9% (14/23) and 85.0% (17/20) respectively. It was significantly higher in partial hydatidiform mole than that in hydropic abortion. A significant difference was also found between partial and complete hydatidiform moles (P<0.05).</p><p><b>CONCLUSIONS</b>Our findings confirm that p57 immunohistochemistry assists the differential diagnosis of complete hydatidiform mole from partial hydatidiform mole. Expression of p53 may be helpful in distinguishing partial hydatidiform mole from hydropic abortion.</p>


Subject(s)
Female , Humans , Pregnancy , Abortion, Spontaneous , Diagnosis , Metabolism , Pathology , Cyclin-Dependent Kinase Inhibitor p57 , Metabolism , Diagnosis, Differential , Hydatidiform Mole , Diagnosis , Metabolism , Pathology , Immunohistochemistry , Stromal Cells , Metabolism , Trophoblasts , Metabolism , Tumor Suppressor Protein p53 , Metabolism , Uterine Neoplasms , Diagnosis , Metabolism , Pathology
SELECTION OF CITATIONS
SEARCH DETAIL